In:
Oncology, S. Karger AG, Vol. 85, No. 5 ( 2013), p. 262-268
Kurzfassung:
〈 b 〉 〈 i 〉 Background: 〈 /i 〉 〈 /b 〉 The role of second-line chemotherapy in advanced gastric cancer is not yet fully established. 〈 b 〉 〈 i 〉 Patients and Methods: 〈 /i 〉 〈 /b 〉 We analysed 111 patients with advanced gastric cancer treated at the University Hospital Heidelberg (51) and the private oncology practice Bottrop/Dorsten (60) between 2001 and 2011, comparing the outcome of patients with first-line chemotherapy and those who received second-line chemotherapy. 〈 b 〉 〈 i 〉 Results: 〈 /i 〉 〈 /b 〉 Thirty-six patients were treated with one chemotherapy regimen, 75 patients received at least two different chemotherapies. Patients who received one chemotherapy regimen were older (median age 69 years) and had a shorter overall survival (6 months) than patients receiving sequential chemotherapies [median age 61 years, p = 0.009, overall survival 14 months (2-42), p = 0.001]. Under second-line chemotherapy, partial response was observed in 25 patients (33%) and stable disease for ≥3 months in 26 patients (35%). Patients treated before 2005 had a slightly better overall survival than patients treated in or after 2005. Survival was not influenced by the treatment centre (primary or tertiary), but was influenced by former surgery. 〈 b 〉 〈 i 〉 Conclusion: 〈 /i 〉 〈 /b 〉 The prognosis of advanced gastric cancer is still poor. Selected patients may benefit from individualized salvage chemotherapy after failure of first-line chemotherapy.
Materialart:
Online-Ressource
ISSN:
0030-2414
,
1423-0232
Sprache:
Englisch
Verlag:
S. Karger AG
Publikationsdatum:
2013
ZDB Id:
1483096-6
ZDB Id:
250101-6
